Price Hike Not Shkreli's Only Antitrust Woe, Experts Argue
While public outrage against the newly convicted Martin Shkreli has largely focused on his 5,000 percent price hike for the drug Daraprim, three pharmaceutical law experts say the Turing Pharmaceuticals founder's...To view the full article, register now.
Already a subscriber? Click here to view full article